GIC backs Esco Lifesciences in oversubscribed US$200m Series A round
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
SINGAPORE-BASED Esco Lifesciences, which supplies life sciences tools for the healthcare industry, has raised US$200 million in an oversubscribed Series A round, as it seeks to expedite expansion in China, and hunt down acquisitions worldwide.
The company is preparing to go public in Hong Kong in the coming months, according to a person familiar with the matter, after its latest round valued it at over US$800 million following the fundraising.
The fundraising, also billed as its crossover round, was led by US-based healthcare investment firm Vivo Capital and Denmark-based life science investor Novo Holdings, the venture arm of Novo Nordisk Foundation.
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Copyright SPH Media. All rights reserved.
TRENDING NOW
‘Boring’ is the new black: The stars are aligning for a Singapore stock market revival
Near sell-out launches in March boost developer sales to 1,300 units after four slow months
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
Genting Singapore’s Lim Kok Thay receives S$7.5 million pay package for FY2025
